Lana Volokh
pharma & biotech
pharma & biotech

ExoProTher Medical is developing a first-in class oncology therapeutics delivery platform targeting cancers with mutation in gene TP53- the most frequently observed genetic alteration in human.  It uses exosomes, natural nanoparticles produced by most living cells, to deliver healthy p53 and restore the body’s natural tumor suppression function with minimal adverse side effects.